Cetuximab for treating non-small cell lung cancer
L Mazzarella, A Guida, G Curigliano - Expert opinion on biological …, 2018 - Taylor & Francis
ABSTRACT Introduction: Epidermal Growth Factor Receptor (EGFR)-dependent signaling
plays a crucial role in epithelial cancer biology, and dictated the development of several …
plays a crucial role in epithelial cancer biology, and dictated the development of several …
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
CA Reade, AK Ganti - Biologics: Targets and Therapy, 2009 - Taylor & Francis
Chemotherapy alone has limited ability to significantly improve survival in non-small lung
cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor …
cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor …
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
8007 Background: The multinational, randomized, phase III FLEX study compared
cisplatin/vinorelbine (CT) plus the EGFR-antibody, cetuximab (Erbitux), with CT alone in the …
cisplatin/vinorelbine (CT) plus the EGFR-antibody, cetuximab (Erbitux), with CT alone in the …
[HTML][HTML] Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
A Sgambato, F Casaluce, P Maione… - Journal of thoracic …, 2014 - ncbi.nlm.nih.gov
© Pioneer Bioscience Publishing Company. All rights reserved. J Thorac Dis 2014; 6 (6):
578-580 www. jthoracdis. com plus gemcitabine in chemo-naïve patients with advanced …
578-580 www. jthoracdis. com plus gemcitabine in chemo-naïve patients with advanced …
Cetuximab in non-small-cell lung cancer
G Carillio, A Montanino, R Costanzo… - Expert Review of …, 2012 - Taylor & Francis
Cetuximab is a chimeric human–mouse anti-EGF receptor monoclonal antibody. In Phase I
studies, no dose-limiting toxicities were observed with cetuximab as a single agent or …
studies, no dose-limiting toxicities were observed with cetuximab as a single agent or …
[HTML][HTML] Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of …
EM Ibrahim, KM Abouelkhair, OA Al-Masri, NC Chaudry… - Lung, 2011 - Springer
Randomized controlled trails (RCTs) where cetuximab added to first-line platinum-based
chemotherapy for patients with advanced/metastatic non-small-cell lung cancer (NSCLC) …
chemotherapy for patients with advanced/metastatic non-small-cell lung cancer (NSCLC) …
[HTML][HTML] Cetuximab in non-small-cell lung cancer
R Pirker, M Filipits - Translational lung cancer research, 2012 - ncbi.nlm.nih.gov
Cetuximab is a chimeric monoclonal antibody that is directed towards the epidermal growth
factor receptor (EGFR). It has been evaluated in combination with first-line chemotherapy in …
factor receptor (EGFR). It has been evaluated in combination with first-line chemotherapy in …
Cetuximab in advanced non-small cell lung cancer
R Govindan - Clinical cancer research, 2004 - AACR
The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell
lung cancer (NSCLC). EGFR activation results in phosphorylation of several downstream …
lung cancer (NSCLC). EGFR activation results in phosphorylation of several downstream …
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
Objectives Four randomized phase II/III trials investigated the addition of cetuximab to
platinum-based, first-line chemotherapy in patients with advanced non-small cell lung …
platinum-based, first-line chemotherapy in patients with advanced non-small cell lung …
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non–small-cell …
S Khambata-Ford, CT Harbison, LL Hart… - Journal of clinical …, 2010 - ascopubs.org
Purpose The anti–epidermal growth factor receptor (EGFR) antibody cetuximab is
efficacious in multiple tumor types. Patient selection with markers predictive of benefit may …
efficacious in multiple tumor types. Patient selection with markers predictive of benefit may …